Two figures, both for the first month only
The pricing page publishes a compounded semaglutide figure and a compounded tirzepatide figure, each labelled as a first month. Nothing on the page states a rate for any month after that.
That is why this row records both as figures whose period is not monthly, rather than as introductory rates. An introductory rate is a temporary price sitting beside an ongoing one; here the ongoing one does not exist on any page read, so there is nothing for a discount to be a discount from.
The practical consequence is simple and it is not small. A reader can find out what starting costs and cannot find out what continuing costs, and continuing is what a GLP-1 programme is.
A published refusal to publish
The pricing page is a two-tab control, and the membership tab carries a new-patient visit cost with a list of what it includes: an assessment, lab work and an eligibility review. Then it stops. The monthly programme options are described as six-month, three-month and one-month plans with no figure attached to any of them.
The page then says why, in its own words: self-pay monthly membership fees vary by programme and by location, additional costs may apply for labs, medications, supplements and specialised treatments, and a reader should contact the local clinic for complete pricing. That sentence is the evidence, and it is quoted on the row rather than summarised as not published.
Twenty-one of the seventy-three sellers here bill a membership apart from the medication. What this one adds is a stated reason for the gap, which is more than an unexplained silence gives a reader.
The membership programme also states that it includes no medication, so the two charges cannot be confused. A headline figure here is never the whole bill.
The other figure on the page is conditioned on insurance
Under the insurance tab the page gives a per-visit range for patients using insurance, running from nothing to a modest amount depending on coverage and deductible status.
That is a range, and it is conditioned on having insurance, so it is neither a cash price nor a single figure. It is not recorded on this row for either reason. A reader comparing this seller against cash-pay sellers is not comparing that number against anything.
The brand-name route is described the same way: name-brand medication, if covered by insurance. So the approved products listed here are an insurance route, not a published cash one.
Five products, and one of them is scarce
The page lists five products with an availability flag beside each: two approved injectables, an approved liraglutide, and the two compounded preparations. Forty-one of the seventy-three sellers here offer a brand route of some kind.
The liraglutide listing is the notable one. Five of the seventy-three sellers here publish a liraglutide price of any kind, and a listing without a figure is not a price — but naming the product at all puts this seller among the few that reach a molecule this comparison barely covers.
Fifty-three of the seventy-three sellers here name no compounding pharmacy, and thirty-three name no individual prescribing clinician. This row is in both groups. The sitewide disclaimer about compounded products is present and clear; the pharmacy behind them is not named.
A clinic count, not a footprint, and a terms document out of step
The chain publishes a clinic count and a zip-code finder with individual clinic addresses. A directory of addresses is not a list of states, and forty-one of the seventy-three sellers here publish no service area at all. This row is one of them.
The terms name three separate entities and a governing-law state with an arbitration venue, which is fuller corporate disclosure than much of this comparison offers. They also describe a different domain from the one serving them, which is a sign a document has not kept pace with the site it governs.
Because pricing varies by location by the seller's own statement, the local clinic is the only place a full answer exists. That is a real limitation of an in-person franchise rather than an evasion, and it is the thing to plan around here.
Medi-Weightloss's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $99A first-month price with no second month published: "GLP-1 Medication Options — Name brand medication, if covered by your insurance · Compounded semaglutide $99 first month · Compounded tirzepatide $199 first month · FSA & HSA eligible". Nothing on the page states what month two costs. | September 2026source |
| Tirzepatide (compounded) | $199The second of the two first-month figures on the same card: "Compounded tirzepatide $199 first month", listed under "GLP-1 Medication Options" with "FSA & HSA eligible" beside it. No month-two rate appears anywhere on the page. | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 73 providers reviewed here are paid partners today; the other 69 are not. See how this works.
See Medi-Weightloss's current price →Good fit if
- Readers who want an in-person clinic programme and a published first-month medication figure rather than nothing at all.
- Buyers who will ring a local clinic for the recurring fee and want to know what to ask for before they do.
- People who want an approved liraglutide named among the options, which very little of this comparison reaches.
- Anyone who wants the programme and the medication billed separately and said so plainly.
Look elsewhere if
- Anyone who needs to know the ongoing cost before starting. No page states what a second month costs.
- Readers paying cash for an approved product. The brand route here is described as an insurance route.
- Buyers who want a national answer. Pricing varies by location by the seller's own statement.
- People who need the compounding pharmacy or an individual prescriber named.
- Readers who need their state confirmed. What is published is a clinic count and a directory, not a service area.
How this review was verified
- Operated both tabs on the pricing page individually, by their own visible labels, and compared the page's visible text length before and after each, because a blanket clicker collapses pages of this kind rather than opening them.
- Recorded both medication figures as first-month prices with a period that is not monthly, so no template prints a monthly suffix beside a rate the seller only claims for one month.
- Did not record them as introductory offers. An introductory offer needs an ongoing rate beside it, and no page read states one.
- Recorded the new-patient visit cost inside the membership field with the seller's own refusal to publish a recurring figure quoted verbatim beside it, rather than converting a refusal into a number.
- Excluded the per-visit range under the insurance tab. It is a range, and it is conditioned on having insurance, so it is neither a cash price nor a figure.
- Recorded the liraglutide product as listed rather than priced, because the availability flag is not a figure.
- Recorded a clinic count and a directory of addresses as what they are, and did not convert either into a list of states.
- Took the three operating entities, the governing-law state and the arbitration venue from the terms verbatim, and recorded that the terms describe a different domain from the one serving them.
- Searched the agency's published warning-letter record for the trading name, both spellings, and for the holding entity, 2017 to 2026, and read every returned row: none of them names this company. That search covers warning letters only; untitled letters are published separately and were not searched.